Key result
Direct oral anticoagulants are non-inferior to low-molecular-weight heparin in preventing recurrent venous thromboembolism in patients with cancer, though they may increase bleeding risk in gastrointestinal cancers.
Why the study?
Knowledge regarding direct oral anticoagulants for cancer-associated venous thromboembolism has expanded, prompting a review of recent major pivotal trials comparing DOACs with low-molecular-weight heparin and their use in challenging clinical situations.
Do DOACs reduce recurrent VTE compared to LMWH in patients with cancer-associated VTE?
Do DOACs reduce recurrent VTE compared to LMWH in patients with cancer-associated VTE?
DOACs are an effective and convenient alternative to LMWH for cancer-associated VTE, but require careful patient selection regarding bleeding risk, renal function, and drug interactions.
Venous thromboembolism (VTE) is a common complication among patients with cancer and is associated with delays in underlying cancer treatment and increases in morbidity and mortality. Acute and long-term treatments with low-molecular-weight-heparin (LMWH) have been recommended as a standard of care for patients with cancer with VTE for the past 20 years. Direct oral anticoagulants (DOACs) have recently emerged as a new therapeutic modality for cancer-associated VTE because of the convenience of oral administration and rapid onset of action. Our knowledge regarding DOACs for cancer-associated VTD has expanded in recent years. Thus, this study aimed to review recent major pivotal trials comparing DOACs with LMWH for managing cancer-associated VTE. Moreover, a recently updated understanding of DOACs in the treatment of cancer-associated VTE in specific challenging situations is presented.
No takes yet. Share an insight, caveat, or question.
Ho‐Young Yhim (2022) conducted a review in Cancer-associated venous thromboembolism. Direct oral anticoagulants (DOACs) vs. Low-molecular-weight-heparin (LMWH) was evaluated. Direct oral anticoagulants are non-inferior to low-molecular-weight heparin in preventing recurrent venous thromboembolism in patients with cancer, though they may increase bleeding risk in gastrointestinal cancers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: